Orphan Drug Status Granted For Revimmune In Treatment of Systemic Sclerosis PDF Print E-mail
Thursday, 23 June 2011 09:40
Accentia Biopharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to RevimmuneTM, the company's proprietary system-of-care based on high-dose administration of Cytoxan(R) (cyclophosphamide), for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia. Based on a an exclusive world-wide license from Johns Hopkins University, Accentia intends to conduct multiple clinical trials evaluating Revimmune therapy for the treatment of a range of autoimmune diseases including multiple sclerosis.

With FDA Orphan Drug Status, Accentia gains seven years of market exclusivity for Revimmune for systemic sclerosis and autoimmune hemolytic anemia upon its approval by the FDA thereby offering competitive protection from similar drugs of the same class. Orphan Drug Status also provides Accentia with eligibility to receive potential tax credit benefits, potential grant funding for research and development and significantly reduces the requisite filing fees for marketing applications.

Accentia's Chief Scientific Officer, Dr. Carlos Santos, Ph.D., commented, "There is an urgent unmet medical need for new treatments for systemic sclerosis and autoimmune hemolytic anemia, as nearly 100,000 patients in the U.S. alone are living with one of these highly debilitating and often deadly autoimmune diseases. Current treatment options, especially in severe cases, are limited with some patients left with no choice but to endure high-risk treatment approaches. However, preliminary open label studies conducted by physicians at Johns Hopkins University have shown that Revimmune therapy is capable of 'rebooting' the immune system by eliminating the circulating cells perpetuating the autoimmunity for patients suffering from either systemic sclerosis or autoimmune hemolytic anemia. Studies published by Johns Hopkins researchers have shown that the majority of those patients treated with Revimmune therapy achieved meaningful clinical benefit and in some cases even underwent complete remissions"

Source: MarketWatch (2011), "Accentia Biopharmaceuticals Announces that FDA grants Orphan Drug Status for Revimmune(TM) Therapy for the Treatment of Two Autoimmune Diseases: Systemic Sclerosis & Hemolytic Anemia"; original article can be found here.

 
More articles :

» Medical Research Trends to Watch in 2012

1. NCATS: Who moved my cheese?This year, the National Institutes of Health will establish its new (NCATS), created to speed the translation of basic discoveries into therapies that will improve public health. Solutions can be tough to develop, and...

» The Dendritic Cell and The Link between Atherosclerosis and Autoimmunity

Individuals who suffer from autoimmune diseases also display a tendency to develop – the condition popularly known as hardening of the arteries. Clinical researchers at LMU, in collaboration with colleagues in Würzburg, have now discovered a...

» Why Your Kids Need Vitamin D

Have you checked with your doctor whether your child is getting enough vitamin D needed for his or her growth? According to CDC, only 5% to 13% of breastfed babies and 20% to 37% of formula-fed infants are getting as much vitamin D as the newly...

» Calcinosis

Background:The Foundation has recently received some feedback from some members of the public asking for more information regarding the condition known as Calcinosis. As part of our efforts we sought to provide a brief, yet informative insight into...

» Anticoagulation of Systemic Sclerosis Patients In Question

Australia is in a state of ‘clinical equipoise’ over whether to anticoagulate systemic sclerosis patients with pulmonary hypertension, experts say. And with observational studies showing the treatment is associated with a  fivefold...

» Scleroderma and Massage Therapy

In a recent patient group meeting, we had the immense pleasure and honour of sitting with Rinalda, a local massage therapist, to discuss the importance of massage therapy and how it can help with our Scleroderma.Rinalda noted that from the beginning...